# Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

> **NCT05240456** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 70 (estimated)

## Conditions studied

- Voiding Disorders
- Overactive Bladder

## Interventions

- **DRUG:** Beta3-Agonists, Adrenergic
- **DRUG:** Anticholinergic drug, Solifenacin

## Key facts

- **NCT ID:** NCT05240456
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02
- **Primary completion:** 2022-07
- **Final completion:** 2022-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240456, "Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05240456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*